JP2547207B2 - 置換ジフエニルエチレン誘導体 - Google Patents

置換ジフエニルエチレン誘導体

Info

Publication number: JP2547207B2
Authority: JP; Japan
Prior art keywords: cyano; formula; acceptable salt; pentenoic acid; substituted
Prior art date: 1986-03-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

JP62060022A

Other languages

English (en)

Japanese (ja)

Other versions

JPS6310743A (ja

Inventor

洋二山岸

光三赤坂

赳鈴木

光明宮本

浩司中本

和夫岡野

信也阿部

博憲生田

憲司林

寛幸吉村

徹藤森

耕吉原田

功山津

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Eisai Co Ltd

Original Assignee

Eisai Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1986-03-17

Filing date

1987-03-17

Publication date

1996-10-23

1987-03-17 Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd

1988-01-18 Publication of JPS6310743A publication Critical patent/JPS6310743A/ja

1996-10-23 Application granted granted Critical

1996-10-23 Publication of JP2547207B2 publication Critical patent/JP2547207B2/ja

2011-10-23 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical group C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 title claims description 16
150000001875 compounds Chemical class 0.000 claims description 20
150000003839 salts Chemical class 0.000 claims description 17
-1 methoxyphenyl Chemical group 0.000 claims description 12
125000003545 alkoxy group Chemical group 0.000 claims description 8
125000000217 alkyl group Chemical group 0.000 claims description 7
229940127218 antiplatelet drug Drugs 0.000 claims description 5
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
239000003146 anticoagulant agent Substances 0.000 claims description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
229960004676 antithrombotic agent Drugs 0.000 claims description 3
125000004093 cyano group Chemical group *C#N 0.000 claims description 3
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
239000004480 active ingredient Substances 0.000 claims description 2
230000000702 anti-platelet effect Effects 0.000 claims 1
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 17
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
239000003814 drug Substances 0.000 description 10
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 8
238000006243 chemical reaction Methods 0.000 description 8
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 8
229910052725 zinc Inorganic materials 0.000 description 8
239000011701 zinc Substances 0.000 description 8
WRECIMRULFAWHA-UHFFFAOYSA-N trimethyl borate Chemical compound COB(OC)OC WRECIMRULFAWHA-UHFFFAOYSA-N 0.000 description 7
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
208000010110 spontaneous platelet aggregation Diseases 0.000 description 6
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 5
230000003197 catalytic effect Effects 0.000 description 5
229910052740 iodine Inorganic materials 0.000 description 5
239000011630 iodine Substances 0.000 description 5
238000000034 method Methods 0.000 description 5
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 4
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 4
238000007796 conventional method Methods 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
OSLJYLDKZWQJCI-UHFFFAOYSA-N ethyl 4-bromo-4-cyanobutanoate Chemical compound CCOC(=O)CCC(Br)C#N OSLJYLDKZWQJCI-UHFFFAOYSA-N 0.000 description 4
239000000203 mixture Substances 0.000 description 4
238000010898 silica gel chromatography Methods 0.000 description 4
239000000243 solution Substances 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
201000010099 disease Diseases 0.000 description 3
229940079593 drug Drugs 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
239000008187 granular material Substances 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000000843 powder Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
208000031104 Arterial Occlusive disease Diseases 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
206010061216 Infarction Diseases 0.000 description 2
208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
YIYBQIKDCADOSF-UHFFFAOYSA-N alpha-Butylen-alpha-carbonsaeure Natural products CCC=CC(O)=O YIYBQIKDCADOSF-UHFFFAOYSA-N 0.000 description 2
229940114079 arachidonic acid Drugs 0.000 description 2
235000021342 arachidonic acid Nutrition 0.000 description 2
208000021328 arterial occlusion Diseases 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
RFVHVYKVRGKLNK-UHFFFAOYSA-N bis(4-methoxyphenyl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)C1=CC=C(OC)C=C1 RFVHVYKVRGKLNK-UHFFFAOYSA-N 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
230000017531 blood circulation Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
208000026106 cerebrovascular disease Diseases 0.000 description 2
PMOWTIHVNWZYFI-WAYWQWQTSA-N cis-2-coumaric acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1O PMOWTIHVNWZYFI-WAYWQWQTSA-N 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
239000003086 colorant Substances 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
230000007574 infarction Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000000106 platelet aggregation inhibitor Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000003826 tablet Substances 0.000 description 2
239000013076 target substance Substances 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
YIYBQIKDCADOSF-ONEGZZNKSA-N trans-pent-2-enoic acid Chemical compound CC\C=C\C(O)=O YIYBQIKDCADOSF-ONEGZZNKSA-N 0.000 description 2
NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
VFTDVICZBGDMMB-UHFFFAOYSA-N (2,4-dimethoxyphenyl)-(4-methoxyphenyl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)C1=CC=C(OC)C=C1OC VFTDVICZBGDMMB-UHFFFAOYSA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
CEHJLVSWCBELNE-SILNSSARSA-N (z)-4-cyano-5-(4-ethoxyphenyl)-5-(4-hydroxyphenyl)pent-4-enoic acid Chemical compound C1=CC(OCC)=CC=C1C(=C(\CCC(O)=O)C#N)\C1=CC=C(O)C=C1 CEHJLVSWCBELNE-SILNSSARSA-N 0.000 description 1
BQTGQTPQTBIRGR-CYVLTUHYSA-N (z)-4-cyano-5-(4-hydroxyphenyl)-5-(4-methoxyphenyl)pent-4-enoic acid Chemical compound C1=CC(OC)=CC=C1C(=C(\CCC(O)=O)C#N)\C1=CC=C(O)C=C1 BQTGQTPQTBIRGR-CYVLTUHYSA-N 0.000 description 1
APHRNCMZHKKRNR-UHFFFAOYSA-N 4-cyano-5,5-bis(4-hydroxyphenyl)pent-4-enoic acid Chemical compound C=1C=C(O)C=CC=1C(=C(C#N)CCC(=O)O)C1=CC=C(O)C=C1 APHRNCMZHKKRNR-UHFFFAOYSA-N 0.000 description 1
CPQBWOTXBMGVES-UHFFFAOYSA-N 4-cyano-5,5-bis(4-methoxyphenyl)-2-methylpent-4-enoic acid Chemical compound C1=CC(OC)=CC=C1C(=C(CC(C)C(O)=O)C#N)C1=CC=C(OC)C=C1 CPQBWOTXBMGVES-UHFFFAOYSA-N 0.000 description 1
125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
208000000575 Arteriosclerosis Obliterans Diseases 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
WVQOSWAWUQEJHM-UHFFFAOYSA-N CCOC1=CC=C(C=C1)C(=C(CC(C)C(=O)O)C#N)C2=CC=C(C=C2)OCC Chemical compound CCOC1=CC=C(C=C1)C(=C(CC(C)C(=O)O)C#N)C2=CC=C(C=C2)OCC WVQOSWAWUQEJHM-UHFFFAOYSA-N 0.000 description 1
RSTVNJJDJGWARD-UHFFFAOYSA-N COC1=C(C(=O)C2=CC=C(C=C2)OC)C=CC(=C1)OCC Chemical compound COC1=C(C(=O)C2=CC=C(C=C2)OC)C=CC(=C1)OCC RSTVNJJDJGWARD-UHFFFAOYSA-N 0.000 description 1
241000700198 Cavia Species 0.000 description 1
206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
206010008132 Cerebral thrombosis Diseases 0.000 description 1
244000223760 Cinnamomum zeylanicum Species 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
206010051055 Deep vein thrombosis Diseases 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
206010061819 Disease recurrence Diseases 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
PTVSRINJXWDIKP-UHFFFAOYSA-N Ethyl 4-pentenoate Chemical compound CCOC(=O)CCC=C PTVSRINJXWDIKP-UHFFFAOYSA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
206010016717 Fistula Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
101100435109 Homo sapiens PRNP gene Proteins 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
201000001429 Intracranial Thrombosis Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
206010050902 Postoperative thrombosis Diseases 0.000 description 1
208000010378 Pulmonary Embolism Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
238000006680 Reformatsky reaction Methods 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
244000299461 Theobroma cacao Species 0.000 description 1
235000009470 Theobroma cacao Nutrition 0.000 description 1
206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010047249 Venous thrombosis Diseases 0.000 description 1
ZFDHCWBUWZVQLV-UHFFFAOYSA-N [4-(methoxymethoxy)phenyl]-(4-methoxyphenyl)methanone Chemical compound C1=CC(OCOC)=CC=C1C(=O)C1=CC=C(OC)C=C1 ZFDHCWBUWZVQLV-UHFFFAOYSA-N 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
238000011047 acute toxicity test Methods 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
210000000702 aorta abdominal Anatomy 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
XZNQFPSOLGYVDO-UHFFFAOYSA-N bis(4-ethoxyphenyl)methanone Chemical compound C1=CC(OCC)=CC=C1C(=O)C1=CC=C(OCC)C=C1 XZNQFPSOLGYVDO-UHFFFAOYSA-N 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229940116229 borneol Drugs 0.000 description 1
CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
244000309464 bull Species 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
239000001354 calcium citrate Substances 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
206010008118 cerebral infarction Diseases 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
235000017803 cinnamon Nutrition 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000012043 crude product Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
GHXXCVVSJXZBPO-UHFFFAOYSA-N ethyl 4-cyanobutanoate Chemical compound CCOC(=O)CCCC#N GHXXCVVSJXZBPO-UHFFFAOYSA-N 0.000 description 1
OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
AGMKVZDPATUSMS-UHFFFAOYSA-N ethyl pent-2-enoate Chemical compound CCOC(=O)C=CCC AGMKVZDPATUSMS-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
230000003890 fistula Effects 0.000 description 1
229940014259 gelatin Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
239000001341 hydroxy propyl starch Substances 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
235000013828 hydroxypropyl starch Nutrition 0.000 description 1
229940071676 hydroxypropylcellulose Drugs 0.000 description 1
239000005457 ice water Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
125000002346 iodo group Chemical group I* 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000001525 mentha piperita l. herb oil Substances 0.000 description 1
229940041616 menthol Drugs 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000012046 mixed solvent Substances 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
235000019477 peppermint oil Nutrition 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
230000000704 physical effect Effects 0.000 description 1
210000002381 plasma Anatomy 0.000 description 1
210000004623 platelet-rich plasma Anatomy 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
229920001289 polyvinyl ether Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
239000004208 shellac Substances 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
235000013337 tricalcium citrate Nutrition 0.000 description 1
AJSTXXYNEIHPMD-UHFFFAOYSA-N triethyl borate Chemical compound CCOB(OCC)OCC AJSTXXYNEIHPMD-UHFFFAOYSA-N 0.000 description 1
208000019553 vascular disease Diseases 0.000 description 1
238000007631 vascular surgery Methods 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Landscapes

Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)

JP62060022A 1986-03-17 1987-03-17 置換ジフエニルエチレン誘導体 Expired - Fee Related JP2547207B2 (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP61-57061		1986-03-17
JP5706186		1986-03-17

Related Child Applications (2)

Application Number	Title	Priority Date	Filing Date
JP6021138A Division JP2608382B2 (ja)	1986-03-17	1994-02-18	置換ジフェニルエチレン誘導体
JP700196A Division JP2594420B2 (ja)	1986-03-17	1996-01-19	置換ジフェニルエチレン誘導体

Publications (2)

Publication Number	Publication Date
JPS6310743A JPS6310743A (ja)	1988-01-18
JP2547207B2 true JP2547207B2 (ja)	1996-10-23

Family

ID=13044927

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP62060022A Expired - Fee Related JP2547207B2 (ja)	1986-03-17	1987-03-17	置換ジフエニルエチレン誘導体

Country Status (4)

Country	Link
JP (1)	JP2547207B2 (de)
DD (4)	DD283373A5 (de)
RU (2)	RU1797606C (de)
SU (1)	SU1715204A3 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2144814C1 (ru) *	1998-06-11	2000-01-27	Корявин Александр Александрович	Ситалл для изготовления зубных протезов

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1357722A (en) *	1972-03-23	1974-06-26	Motorola Inc	Tape head indexing assembly for cartridge tape player including a rotary solenoid

1987
- 1987-03-16 DD DD32489187A patent/DD283373A5/de not_active IP Right Cessation
- 1987-03-16 DD DD32489087A patent/DD278782A5/de not_active IP Right Cessation
- 1987-03-16 DD DD32489287A patent/DD278780A5/de not_active IP Right Cessation
- 1987-03-16 DD DD87300831A patent/DD263233A5/de not_active IP Right Cessation
- 1987-03-17 JP JP62060022A patent/JP2547207B2/ja not_active Expired - Fee Related
1989
- 1989-02-27 RU SU894613517A patent/RU1797606C/ru active
- 1989-02-28 SU SU894613563A patent/SU1715204A3/ru active
1992
- 1992-01-15 RU SU5010552 patent/RU2034831C1/ru active

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ｂｕｌｌ．Ｓｏｃ．Ｃｈｉｍ．Ｆｒ．（１２），３８９５−３９００，１９６６

Also Published As

Publication number	Publication date
JPS6310743A (ja)	1988-01-18
RU2034831C1 (ru)	1995-05-10
RU1797606C (ru)	1993-02-23
DD278780A5 (de)	1990-05-16
DD263233A5 (de)	1988-12-28
DD278782A5 (de)	1990-05-16
SU1715204A3 (ru)	1992-02-23
DD283373A5 (de)	1990-10-10

Legal Events

Date	Code	Title	Description
2003-08-08	LAPS	Cancellation because of no payment of annual fees

Publication	Publication Date	Title
JP3045017B2 (ja)	2000-05-22	スチルベン誘導体及びそれを含有する制癌剤
JP2919030B2 (ja)	1999-07-12	キノン誘導体
CA1196637A (fr)	1985-11-12	Composes de la serie des benzoxepines et analogues soufres et azotes, leur procedes et utilisations en tant que medicament
FI92189B (fi)	1994-06-30	Menetelmä lääkeaineina käyttökelpoisen difenyylimetaanijohdannaisen valmistamiseksi
WO1991016338A1 (fr)	1991-10-31	Derive de glutathion a substitution-s-(acide gras inferieur)
KR900008113B1 (ko)	1990-10-31	플루오로알릴아민 유도체 및 이의 제조방법
EP0223674A1 (de)	1987-05-27	7-Acyl-benzoxazinone und deren Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen
US4237165A (en)	1980-12-02	Treatment of carbohydrate metabolism disorders
JP2594420B2 (ja)	1997-03-26	置換ジフェニルエチレン誘導体
FR2610932A1 (fr)	1988-08-19	Nouvel acide piperazinecarboxylique, sa preparation et son utilisation comme medicament
JPS61275274A (ja)	1986-12-05	１，３−ジチオ−ル−２−イリデン誘導体及びその用途
US4611057A (en)	1986-09-09	Process for preparing pyrimidinetrione derivatives
JP3032053B2 (ja)	2000-04-10	ウリジン誘導体及びこれを含有する医薬
HU180617B (en)	1983-03-28	Process for producing 1,2-bis-bracket-nicotinamido-bracket closed-propane,salts and pharmaceutical compositions containing them
EP0146920B1 (de)	1988-02-17	Verbindungen mit mündlicher inotropischer Wirkung
JPH0514708B2 (de)	1993-02-25
US2899358A (en)	1959-08-11	Process
JPH07103082B2 (ja)	1995-11-08	置換ベンゾフエノンオキシムエ−テル誘導体
EP0103897B1 (de)	1987-02-04	Pharmazeutische Zusammensetzungen verwendbar für die Verbesserung und/oder Behandlung von durch organische Störungen im Hirn verursachten geistigen Symptomen
JPH05503510A (ja)	1993-06-10	光学的に純粋な（ｓ）―アテノロールを含む組成物と方法
JP2608382B2 (ja)	1997-05-07	置換ジフェニルエチレン誘導体
JPH0680582A (ja)	1994-03-22	脂質代謝改善剤
RU2034831C1 (ru)	1995-05-10	Дифенилэтиленовые производные
US3781444A (en)	1973-12-25	Hypocholesterolemic compounds
HU202858B (en)	1991-04-29	Process for producing 4h-benzo(4,5)cyclohepta(1,2-b)thiophene derivatives